A data-driven approach for predicting the impact of drugs on the human microbiome
Open accessPublished version of a preprint
The DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
Many medications can negatively impact the bacteria residing in our gut, depleting beneficial species, and causing adverse effects. To guide personalized pharmaceutical treatment, a comprehensive understanding of the impact of various drugs on the gut microbiome is needed, yet, to date, experimentally challenging to obtain. Towards this end, we develop a data-driven approach, integrating information about the chemical properties of each drug and the genomic content of each microbe, to systematically predict drug-microbiome interactions. We show that this framework successfully predicts outcomes of in-vitro pairwise drug-microbe experiments, as well as drug-induced microbiome dysbiosis in both animal models and clinical trials. Applying this methodology, we systematically map a large array of interactions between pharmaceuticals and human gut bacteria and demonstrate that medications’ anti-microbial properties are tightly linked to their adverse effects. This computational framework has the potential to unlock the development of personalized medicine and microbiome-based therapeutic approaches, improving outcomes and minimizing side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In silico models further reveal that lipophilicity and charge distribution best predict a molecule’s anti-commensal potency, with PPIs, immunosuppressants, and antineoplastic drugs ranking among the most dysbiotic.101”
From Gut dysbiosis in oncology: a risk factor for immunoresistance (2026) · doi:10.1038/s41422-025-01212-6 · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 80 · Cited by 54
Metadata
- Authors
- Algavi, Y. M., & Borenstein, E.
- Affiliations
- Tel Aviv University (IL)
- Santa Fe Institute (US)
- Corresponding author
- Borenstein, Elhanan
- Venue
- Nature Communications
- Published
- 2023-06-17
- Volume
- 14
- Issue
- 1
- Pages
- 3614-3614
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC10276880
- OpenAlex
- W4381051893
- Cited by
- 54
- References
- 80
- Citations by year
- 2026: 22 · 2025: 20 · 2024: 12
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (U19AG057377)
- Israel Science Foundation (2435/19)
- Faculty Fellow of the Edmond J. Safra Center for Bioinformatics at Tel Aviv University.
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- drug-microbiome interactions, gut microbiota, adverse drug reactions, personalized medicine, microbiota-based therapy
- MeSH terms
- Gastrointestinal Microbiome, Animals, Humans, Genomics, Microbiota, Drug-Related Side Effects and Adverse Reactions, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A data-driven approach for predicting the impact of drugs on the human microbiome. https://app.cochat.ai/papers/10.1038/s41467-023-39264-0
- The paper
- Algavi, Y. M., & Borenstein, E. (2023). A data-driven approach for predicting the impact of drugs on the human microbiome. Nature Communications. https://doi.org/10.1038/s41467-023-39264-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.